Browsing: Receptor

It has been 12 years since the first GLP-1 receptor agonist, liraglutide (Saxenda), was approved as a weight loss medication. This breakthrough was followed in 2021 by the approval of semaglutide (Wegovy) and in 2023 by the approval of tirzepatide (Zepbound), which have transformed obesity treatment

Background: The popularity of GLP-1 receptor agonists (GLP-1 RAs) for weight loss has increased significantly in recent years, raising concerns about self-medication with these medications. Objective: To assess the proportion and identify factors associated with GLP-1 RA use without medical prescription among GLP-1 RA users in Brazil. Methods: This cross-sectional study was conducted through a…

VCT220 is a novel nonpeptide, orally available glucagon-like peptide-1 receptor agonist (GLP-1RA) designed to reduce the complex administration of injectable GLP-1RAs and the limited bioavailability of on-marketing oral agents for obesity care. We conducted a multicenter, randomized, double-blind, placebo-controlled, phase II trial (Registration no. CTR20233978 and NCT06569355) across 13 sites in China. Adults aged 18–75…

Social media has labelled GLP-1 receptor agonists as “miracle” weight-loss drugs. However, these medicines represent more than a passing trend. Obesity is a complex chronic disease often associated with diabetes, hypertension and cardiovascular problems. GLP-1 receptor agonists, initially developed for type 2 diabetes, now play an important role in obesity management

NEW real-world evidence shows that GLP-1 receptor agonists significantly reduce joint pain and inflammation in psoriatic arthritis. Patients living with psoriatic arthritis frequently experience a heavy metabolic disease burden, with concomitant obesity operating as a primary driver of heightened systemic inflammation, severe disease activity, and reduced response to biological therapies. To evaluate the therapeutic potential…

This is a paid press release. Contact the press release distributor directly with any enquiries.

1 receptor agonists may reduce obesity related cancer risk through metabolic and direct cellular mechanisms, according to new evidence

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) exposures reported to U.S. poison centers increased following 2021 U.S. Food and Drug Administration (FDA) approval for weight loss, according to a study published in the April issue of the Journal of Medical Toxicology